Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schecter

Showing results (31-40 of 74) with videos related to

Pageof 8
Sort By:
Clinical Drug Investigation|November 25, 2021
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaKatja Weisel, Thomas Martin, Amrita Krishnan, et al.
Cancers|December 10, 2021
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German RegistryMaximilian Merz, Hartmut Goldschmidt, Parameswaran Hari, et al.
BMC Bioinformatics|March 8, 2020
CNV Radar: an improved method for somatic copy number alteration characterization in oncologyDavid Soong, Jeran Stratford, Herve Avet-Loiseau, et al.
British Journal of Haematology|April 2, 2019
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 studyTorben Plesner, Hendrik-Tobias Arkenau, Francesca Gay, et al.
Current Medical Research and Opinion|October 22, 2022
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myelomaTom Martin, Saad Z Usmani, Jordan M Schecter, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 3, 2020
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTORMaria-Victoria Mateos, Pieter Sonneveld, Vania Hungria, et al.
Clinical Chemistry and Laboratory Medicine|December 9, 2016
Response to: Interference of daratumumab on the serum protein electrophoresisChristopher McCudden, Amy E Axel, Dominique Slaets, et al.
Clinical Chemistry and Laboratory Medicine|March 31, 2016
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interferenceChristopher McCudden, Amy E Axel, Dominique Slaets, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2024
Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trialsKwee Yong, Hermann Einsele, Jordan M Schecter, et al.
Cancer Medicine|July 28, 2025
Real-World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1-3 Prior Lines of Therapy: Optum DatabaseBinod Dhakal, Hermann Einsele, Jordan M Schecter, et al.
Pageof 8

Showing results (31-40 of 74) with videos related to

Sort By:
Pageof 8
Clinical Drug Investigation|November 25, 2021
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaKatja Weisel, Thomas Martin, Amrita Krishnan, et al.
Cancers|December 10, 2021
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German RegistryMaximilian Merz, Hartmut Goldschmidt, Parameswaran Hari, et al.
BMC Bioinformatics|March 8, 2020
CNV Radar: an improved method for somatic copy number alteration characterization in oncologyDavid Soong, Jeran Stratford, Herve Avet-Loiseau, et al.
British Journal of Haematology|April 2, 2019
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 studyTorben Plesner, Hendrik-Tobias Arkenau, Francesca Gay, et al.
Current Medical Research and Opinion|October 22, 2022
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myelomaTom Martin, Saad Z Usmani, Jordan M Schecter, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 3, 2020
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTORMaria-Victoria Mateos, Pieter Sonneveld, Vania Hungria, et al.
Clinical Chemistry and Laboratory Medicine|December 9, 2016
Response to: Interference of daratumumab on the serum protein electrophoresisChristopher McCudden, Amy E Axel, Dominique Slaets, et al.
Clinical Chemistry and Laboratory Medicine|March 31, 2016
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interferenceChristopher McCudden, Amy E Axel, Dominique Slaets, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2024
Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trialsKwee Yong, Hermann Einsele, Jordan M Schecter, et al.
Cancer Medicine|July 28, 2025
Real-World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1-3 Prior Lines of Therapy: Optum DatabaseBinod Dhakal, Hermann Einsele, Jordan M Schecter, et al.
Pageof 8